Evidence map›Paper›PMID 26258150›Full record

ReviewJournal of immunology research2015

Sepsis: From Pathophysiology to Individualized Patient Care.

Ildikó László, Domonkos Trásy, Zsolt Molnár, János Fazakas

3 registry-linked trialsOpen access · goldAbstract readReview
In one paragraph

Review in Journal of immunology research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 41 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 2 pooled it
5.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04742764 phase3suspendednot on this mapstarted 2024, after this paper: background citation

Dosing of Extracorporeal Cytokine Removal In Septic Shock (DECRISS): a Prospective, Randomized, Multicenter Clinical Trial

TypeinterventionalSponsorUniversity of PecsRan2024 to 2027Enrolled135ConditionsSeptic ShockArmsStandard medical therapy, Standard medical therapy plus cytokine removal treatment using Cytosorb, with the adsorber changed in every 12 hours, Standard medical therapy plus cytokine removal treatment using Cytosorb, with the adsorber changed in every 24 hours
NCT05042622 naunknown statusnot on this mapstarted 2021, after this paper: background citation

Innovative Solutions to Organ-substituting Technologies in the Treatment of Heart and Pulmonary Failure

TypeinterventionalSponsorNational Research Center for Cardiac Surgery, KazakhstanRan2021 to 2023Enrolled90ConditionsAcute Respiratory Distress Syndrome, Septic Shock, SepsisArmsCytokine adsorber filter, Extracorporeal hemoperfusion cartridge
NCT05090930 naunknown statusnot on this mapstarted 2021, after this paper: background citation

Development of Innovative Technologies for the Treatment of Pulmonary and Heart Failure to Prolong Human's Life

TypeinterventionalSponsorNational Research Center for Cardiac Surgery, KazakhstanRan2021 to 2023Enrolled100ConditionsCardiogenic Shock, Ventricular Arrythmia, Cardiac Arrest With Successful Resuscitation, SepsisArmsHA330 - Jafron Biomedical Co., Ltd., China - extracorporeal hemocorrection, CytoSorb (CytoSorbents Corp., USA) - an extracorporeal cytokine adsorber
3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 2 syntheses or guidelines pooled it, 83 citations in OpenAlex.

  1. Pooled it
  2. Sepsis in Dogs and Cats-Consensus Definition and Clinical Criteria.Journal of veterinary emergency and critical care (San Antonio, Tex. : 2001)
    Pooled it
  3. Article
  4. Review
  5. Article
  6. Article
  7. Clinical phenotypes of sepsis: a narrative review.Journal of thoracic disease · 2024
    Review
  8. Article
  9. Observational
  10. Article
  11. Article
  12. Review
  13. Observational
  14. Article
  15. Septic Shock: Phenotypes and Outcomes.Advances in therapy · 2022
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. High Mobility Group Proteins in Sepsis.Frontiers in immunology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Ildikó LászlóDepartment of Anaesthesiology and Intensive Therapy, Faculty of Medicine, University of Szeged, Szeged 6725, Hungary.
Domonkos TrásyDepartment of Anaesthesiology and Intensive Therapy, Faculty of Medicine, University of Szeged, Szeged 6725, Hungary.
Zsolt MolnárDepartment of Anaesthesiology and Intensive Therapy, Faculty of Medicine, University of Szeged, Szeged 6725, Hungary.
János FazakasDepartment of Transplantation and Surgery, Faculty of Medicine, Semmelweis University, Budapest 1082, Hungary.
University of Szeged · HUSemmelweis University · HU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sepsis has become a major health economic issue, with more patients dying in hospitals due to sepsis related complications compared to breast and colorectal cancer together. Despite extensive research in order to improve outcome in sepsis over the last few decades, results of large multicenter studies were by-and-large very disappointing. This fiasco can be explained by several factors, but one of the most important reasons is the uncertain definition of sepsis resulting in very heterogeneous patient populations, and the lack of understanding of pathophysiology, which is mainly based on the imbalance in the host-immune response. However, this heroic research work has not been in vain. Putting the results of positive and negative studies into context, we can now approach sepsis in a different concept, which may lead us to new perspectives in diagnostics and treatment. While decision making based on conventional sepsis definitions can inevitably lead to false judgment due to the heterogeneity of patients, new concepts based on currently gained knowledge in immunology may help to tailor assessment and treatment of these patients to their actual needs. Summarizing where we stand at present and what the future may hold are the purpose of this review.

Indexed as

Patient CareBiomarkersCalcitoninDisease ManagementHumansProtein PrecursorsSepsisBiomarkersCalcitoninProtein Precursors

Identifiers

PMID26258150
PMCPMC4518174
OpenAlexW1536596144

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.